Another Nitrosamine Impurity Found In Valsartan; ‘Low’ Cancer Risk Seen

Zhejiang Huahai has detected a second probable carcinogen in valsartan API it manufactured. Meanwhile risk analysis suggests cancer risk from the first probable carcinogen is low, at least so far.